Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FURI open-label ibrexafungerp study in refractory or intolerant fungal disease
NL-OMON55351Phase 3Active, not recruiting
- Sponsor
- SCYNEXIS, Inc.
- Start
- May 2019
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ibrexafungerp in candidiasis and mycoses, sponsored by SCYNEXIS, Inc. Primary endpoints: Global success at end of treatment and Safety. Started May 2019; status: active, not recruiting.
02
Drugs
ibrexafungerp
03
Conditions
candidiasismycoses
Beyond the preview
Go deeper on NL-OMON55351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55351.